PORT HUENEME, CA--(Marketwire - June 2, 2010) - Stellar Biotechnologies, Inc. (
Prior to this news, Neovacs had announced that it had entered Phase II human trials with a Stellar KLH-based vaccine for rheumatoid arthritis. http://www.medicalnewstoday.com/articles/173492.php
Stellar's Executive VP, Business Development & Finance Darrell Brookstein said, "Our customer's success in identifying additional indications that respond to KLH conjugate therapy bodes well for Stellar's plan to increase business development across a broad range of potential therapeutics and diagnostics. Both joint ventures and co-research partnerships will be keys to Stellar's advancement in the future, and we invite interest from companies and academic research centers. Our scientific and engineering team, combined with our long experience and intellectual property in KLH manufacture and source animal maintenance bring further value to our association."
About Stellar Biotechnologies, Inc (
About Neovacs Neovacs is a biotechnology company focused on an active immunotherapy technology platform, holds a broad patent portfolio and is developing therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information:
Contact:
Darrell Brookstein
Executive VP
858 449 2523
DBrookstein@StellarBiotech.com